State of the art of genetic alterations in thymic epithelial tumors

Journal of Thoracic Oncology

Volumn 9, Issue 9, 2014, Pages S131-S136

  Rajan, Arun ^a   Girard, Nicolas ^b   Marx, Alexander ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b LOUIS PRADEL HOSPITAL   (France)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chromosomal abnormalities; Gene expression; Gene signatures; Methylation; Sequencing; Thymic carcinoma; Thymoma

Indexed keywords

DNA; TRANSCRIPTOME;

ARTICLE; CHROMOSOME ABERRATION; CLINICAL PRACTICE; DISEASE ASSOCIATION; DNA METHYLATION; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENETIC DISORDER; GENOME; GENOME ANALYSIS; HUMAN; NEUROEPITHELIOMA; PRIORITY JOURNAL; THYMOMA; TRANSCRIPTOMICS; GENETICS; NEOPLASM;

HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; THYMUS NEOPLASMS;

EID: 84964316165     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000298     Document Type: Article

References (57)

1. Girard N. Thymic epithelial tumours: from basic principles to individualised treatment strategies. Eur Respir Rev 2013;22:75-87.
2. Kuo TT. Tumors of the thymus. In Travis WD, Brambilla E, Muller- Hermelink HK, et al., editors. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press, 2004. Pp. 146-248.
3. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25.
4. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368:2059-2074.
5. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
6. Cancer Genome Atlas Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315-322.
7. Cancer Genome Atlas Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-615.
8. Zettl A, Ströbel P, Wagner K, et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 2000;157:257-266.
9. Girard N, Shen R, Guo T, et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009;15:6790-6799.
10. Penzel R, Hoegel J, Schmitz W, et al. Clusters of chromosomal imbalances in thymic epithelial tumours are associated with the WHO classification and the staging system according to Masaoka. Int J Cancer 2003;105:494-498.
11. Inoue M, Starostik P, Zettl A, et al. Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res 2003;63:3708-3715.
12. Weissferdt A, Lin H, Woods D, et al. HER family receptor and ligand status in thymic carcinoma. Lung Cancer 2012;77:515-521.
13. Ionescu DN, Sasatomi E, Cieply K, Nola M, Dacic S. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 2005;103:630-636.
14. Lee GY, Yang WI, Jeung HC, et al. Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization. BMC Genomics 2007;8:305.
15. Petrini I, Wang Y, Zucali PA, et al. Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors. Clin Cancer Res 2013;19:1960-1971.
16. Chen C, Yin N, Yin B, Lu Q. DNA methylation in thoracic neoplasms. Cancer Lett 2011;301:7-16.
17. Suzuki M, Chen H, Shigematsu H, et al. Aberrant methylation: common in thymic carcinomas, rare in thymomas. Oncol Rep 2005;14:1621-1624.
18. Mokhtar M, Kondo K, Namura T, et al. Methylation and expression profiles of MGMT gene in thymic epithelial tumors. Lung Cancer 2014;83:279-287.
19. Hirabayashi H, Fujii Y, Sakaguchi M, et al. p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. Int J Cancer 1997;73:639-644.
20. Petrini I, Meltzer PS, Zucali PA, et al. Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. Cell Death Dis 2012;3:e351.
21. Fahrer J, Kaina B. O6-methylguanine-DNA methyltransferase in the defense against N-nitroso compounds and colorectal cancer. Carcinogenesis 2013;34:2435-2442.
22. Besse B, Garassino M, Rajan A, et al. A phase II study of milciclib (PHA- 848125AC) in patients (pts) with thymic carcinoma (TC). J Clin Oncol (Meeting Abstracts) 2014;32:7526.
23. Badve S, Goswami C, Gökmen-Polar Y, et al. Molecular analysis of thymoma. Plos One 2012;7:e42669.
24. Tammali R, Srivastava SK, Ramana KV. Targeting aldose reductase for the treatment of cancer. Curr Cancer Drug Targets 2011;11:560-571.
25. Ruffini E, Detterbeck F, Van Raemdonck D, et al. Tumours of the thymus: A cohort study of prognostic factors from the European Society of Thoracic Surgeons database. Eur J Cardiothorac Surg 2014 [Epub ahead of print].
26. Sasaki H, Ide N, Yukiue H, et al. Arg and DAP3 expression was correlated with human thymoma stage. Clin Exp Metastasis 2004;21:507-513.
27. Takahashi E, Tateyama H, Akatsu H, et al. Expression of matrix metalloproteinases 2 and 7 in tumor cells correlates with the World Health Organization classification subtype and clinical stage of thymic epithelial tumors. Hum Pathol 2003;34:1253-1258.
28. Sasaki H, Ide N, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y. Gene expression analysis of human thymoma correlates with tumor stage. Int J Cancer 2002;101:342-347.
29. Gökmen-Polar Y, Cook RW, Goswami CP, et al. A gene signature to determine metastatic behavior in thymomas. Plos One 2013;8:e66047.
30. Petrini I, Rajan A, Pham T, et al. Whole genome and transcriptome sequencing of a B3 thymoma. Plos One 2013;8:e60572.
31. Girard N. Thymic tumors: Relevant molecular data in the clinic. J Thorac Oncol 2010;5:S291-S295.
32. Giaccone G, Rajan A, Ruijter R, Smit E, van Groeningen C, Hogendoorn PC. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol 2009;4:1270-1273.
33. Salter JT, Lewis D, Yiannoutsos C, Loehrer PJ Sr., Risley L, Chiorean EG. Imatinib for the treatment of thymic carcinoma. J Clin Oncol (Meeting Abstracts) 2008;26:8116.
34. Kurup A, Burns M, Dropcho S, Pao W, Loehrer PJ. Phase II study of gefitinib treatment in advanced thymic malignancies. J Clin Oncol (Meeting Abstracts) 2005;23:7068.
35. Bedano PM, Perkins S, Burns M, et al. A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol (Meeting Abstracts) 2008;26:19087.
36. Thomas A, Rajan A, Berman AW, et al. Phase II trial of sunitinib in patients with thymic epithelial tumors (TET). J Clin Oncol (Meeting Abstracts) 2014;32:7525.
37. Rajan A, Carter CA, Berman A, et al. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: A multicentre, open-label, phase 2 trial. Lancet Oncol 2014;15:191-200.
38. Palmieri G, Marino M, Buonerba C, et al. Imatinib mesylate in thymic epithelial malignancies. Cancer Chemother Pharmacol 2012;69:309-315.
39. Wakelee HA, Gubens MA, Burns M, et al. A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies. Chicago Multidisciplinary Symposium in Thoracic Oncology, Poster 152, 2010.
40. Giaccone G, Rajan A, Berman A, et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol 2011;29:2052-2059.
41. Zucali PA, De Pas T, Palmieri G, et al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. J Clin Oncol (Meeting Abstracts) 2014;32:7527.
42. Hayashi Y, Ishii N, Obayashi C, et al. Thymoma: Tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21. Virchows Arch 1995;426:43-50.
43. Suzuki E, Sasaki H, Kawano O, et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 2006;36:351-356.
44. Pan CC, Chen PC, Wang LS, Lee JY, Chiang H. Expression of apoptosis- related markers and HER-2/neu in thymic epithelial tumours. Histopathology 2003;43:165-172.
45. Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 2004;202:375-381.
46. Petrini I, Zucali PA, Lee HS, et al. Expression and mutational status of c-kit in thymic epithelial tumors. J Thorac Oncol 2010;5:1447-1453.
47. Nakagawa K, Matsuno Y, Kunitoh H, Maeshima A, Asamura H, Tsuchiya R. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest 2005;128:140-144.
48. Girard N, Teruya-Feldstein J, Payabyab EC, et al. Insulin-like growth factor-1 receptor expression in thymic malignancies. J Thorac Oncol 2010;5:1439-1446.
49. Zucali PA, Petrini I, Lorenzi E, et al. Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer 2010;116:4686-4695.
50. Tomita M, Matsuzaki Y, Edagawa M, et al. Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. J Thorac Cardiovasc Surg 2002;124:493-498.
51. Ganci F, Vico C, Korita E, et al. MicroRNA expression profiling of thymic epithelial tumors. Lung Cancer 2014;85:197-204.
52. Huang B, Belharazem D, Li L, et al. Anti-Apoptotic signature in thymic squamous cell carcinomas-functional relevance of anti-Apoptotic BIRC3 expression in the thymic carcinoma cell line 1889c. Front Oncol 2013;3:316.
53. Radovich M, Porter RF, Conces M, et al. Next-generation sequencing of thymic malignancies. J Clin Oncol (Meeting Abstracts) 2012;30:7032.
54. Wheler J, Hong D, Swisher SG, et al. Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: Responses to mTOR inhibitors and molecular analyses. Oncotarget 2013;4:890-898.
55. Kossai M, Duchemann B, Caramella C, et al. Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development program (phase I trials) at Institut Gustave Roussy. J Clin Oncol (Meeting Abstracts) 2013;31:7604.
56. Giaccone G, Lopez-Chavez A, Thomas A, et al. Custom (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies) trial. J Clin Oncol (Meeting Abstracts) 2013;31:7513.
57. Palmieri G, Buonerba C, Federico P, et al. Everolimus plus long-Acting somatostatin analogs in thymic epithelial malignancies. World J Clin Oncol 2012;3:111-115.